Inspire Medical Systems (INSP) Company Report

A class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) on behalf of investors who purchased common stock between August 6, 2024, and August 4, 2025.
Investors have until January 5, 2026, to seek appointment as lead plaintiff in the lawsuit.
The lawsuit alleges that Inspire Medical and its executives made false and misleading statements and failed to disclose issues with the Inspire V product launch, including weak demand, surplus inventory, provider hesitancy, and incomplete essential groundwork.
On August 4, 2025, Inspire Medical disclosed an "elongated timeframe" for the Inspire V rollout, issues with Medicare billing software updates, and reduced its 2025 earnings guidance by over 80%, leading to a stock price decline of more than 32%.

3 days ago

Press Release

Inspire Medical Systems Faces Investor Lawsuit Following Disastrous Inspire V Launch and Guidance Cut

INSP

Legal Proceedings

Product Launch

Guidance Update

Inspire Medical Systems, Inc. (INSP) is subject to a proposed class-action lawsuit alleging the company misled investors about the commercial readiness and demand for its Inspire V sleep apnea device.
The lawsuit, covering the Class Period of August 6, 2024, to August 4, 2025, claims the Inspire V launch was disastrous due to factors such as incomplete clinician training, delayed billing software updates, and existing inventory of older devices.
Investors learned the truth on August 4, 2025, when Inspire disclosed these headwinds and subsequently slashed its 2025 earnings guidance by 80% to $0.40 to $0.50 per share.
The announcement caused Inspire's shares to crash $42.04, representing a decline of approximately 32%.

4 days ago

Press Release

Inspire Medical Systems, Inc. anticipates significant Q4 2025 income tax benefit

INSP

Accounting Changes

Guidance Update

Inspire Medical Systems, Inc. expects to release a significant portion of the valuation allowance on its U.S. deferred tax assets during the fourth quarter of fiscal 2025.
This release is estimated to result in an income tax benefit ranging from $90 million to $100 million for the year.
The company anticipates this will increase diluted earnings per share by approximately $3.00 to $3.30 for the same period.

5 days ago

8-K

Inspire Medical Systems Faces Investor Lawsuit Over Inspire V Launch

INSP

Legal Proceedings

Product Launch

Guidance Update

Inspire Medical Systems, Inc. (INSP) is facing a proposed class-action lawsuit alleging the company misled investors regarding the commercial readiness and demand for its "next generation" sleep apnea device, the Inspire V.
The lawsuit claims the Inspire V launch was "disastrous" due to minimal initial demand, customers having excess inventory of older Inspire IV devices, and the company allegedly neglecting necessary steps for swift adoption by clinicians and payors.
Investors reportedly learned the truth on August 4, 2025, when Inspire revealed an "elongated timeframe" for the Inspire V launch due to undisclosed headwinds, including centers not completing training/onboarding and CPT code software updates for Medicare patients not taking effect until July 1.
As a result of the launch issues, Inspire slashed its 2025 earnings guidance by 80% to $0.40 to $0.50 per share. This news caused Inspire shares to crash $42.04, a decline of roughly 32%, the next day.
The class period for the lawsuit is August 6, 2024 – August 4, 2025, with a lead plaintiff deadline of January 5, 2026.

Nov 13, 2025, 2:00 PM

Press Release

Inspire Medical Systems Faces Class-Action Lawsuit Over Inspire V Launch Issues

INSP

Legal Proceedings

Guidance Update

Demand Weakening

Inspire Medical Systems, Inc. (INSP) is facing a proposed class-action lawsuit alleging it misled investors about the commercial readiness and demand for its Inspire V sleep apnea device.
The lawsuit, covering the period August 6, 2024, to August 4, 2025, claims the Inspire V launch was a "disaster" due to minimal initial demand and customers' existing inventory of older devices.
On August 4, 2025, Inspire disclosed an "elongated timeframe" for the Inspire V launch, citing issues like incomplete center training, delayed CPT code software updates, and the need for customers to deplete Inspire IV inventory.
As a result, Inspire slashed its 2025 earnings guidance by 80% to $0.40 to $0.50 per share, causing its shares to crash 32%.

Nov 11, 2025, 2:11 PM

Press Release

Inspire Medical Systems Faces Class Action Lawsuit Over Inspire V Product Launch

INSP

Legal Proceedings

Product Launch

Guidance Update

A class action lawsuit has been filed against Inspire Medical Systems, Inc. (NYSE: INSP) on behalf of investors who purchased common stock between August 6, 2024, and August 4, 2025.
The lawsuit alleges that the company made false and misleading statements and failed to disclose that the Inspire V product launch was performing poorly due to weak demand, surplus inventory, and incomplete essential groundwork.
On August 4, 2025, Inspire Medical revealed an "elongated timeframe" for the Inspire V rollout due to these issues, along with delayed Medicare billing software updates and excess channel inventory.
Following this disclosure, Inspire Medical reduced its 2025 earnings guidance by over 80%, and its stock price declined more than 32%.
Investors have until January 5, 2026, to seek appointment as lead plaintiff in the lawsuit.

Nov 11, 2025, 1:27 PM

Press Release

Inspire Medical Systems Reports Successful Inspire 5 Transition and Provides Outlook for Growth

INSP

Product Launch

Guidance Update

Share Buyback

Inspire Medical Systems (INSP) reported a successful Q3 with significant progress in the transition from Inspire 4 to the new Inspire 5 system, with over 98% of centers trained and 75% ready for the new device. The Inspire 5 system offers a 20% reduction in surgical time and simplifies the procedure by incorporating the sensor inside the neurostimulator, removing the need for a pressure-sensing lead.
The company anticipates increased Medicare reimbursement for Ambulatory Surgical Centers (ASCs) to $28,000 starting January 1st, utilizing the new code 64568, which is expected to drive further adoption in ASCs, currently representing only 20% of implants.
INSP provided an early indication of low double-digit (10-11%) top-line growth for the upcoming year, with formal guidance expected in January, while reaffirming its revenue guidance for the current year.
The company is investing in growth initiatives, including a new direct-to-consumer ad campaign, and expects a gross margin boost from Inspire 5. It also has $150 million remaining on its $200 million share repurchase authorization and plans to be opportunistic with buybacks.
Future innovations include Inspire 6, which aims for automated therapy adherence, and recent data presented at ENT conferences showed significant improvements in cardiovascular health for Inspire users, which is expected to strengthen arguments for payer coverage.

Nov 10, 2025, 4:45 PM

Transcript

Inspire Medical Systems Faces Investor Lawsuit Over Inspire V Launch

INSP

Legal Proceedings

Guidance Update

Product Launch

Inspire Medical Systems, Inc. (INSP) is facing a proposed class-action lawsuit alleging the company misled investors about the commercial readiness and demand for its Inspire V sleep apnea device, which led to a dramatic stock crash.
The lawsuit covers the period from August 6, 2024, to August 4, 2025, claiming the Inspire V launch was "disastrous" due to minimal initial demand, customers holding inventory of older Inspire IV devices, and neglected steps for swift adoption by clinicians and payors.
On August 4, 2025, Inspire disclosed an "elongated timeframe" for the Inspire V launch due to previously undisclosed headwinds, including centers not completing training, software updates for claims submissions not taking effect until July 1, and customers needing to "burn down" Inspire IV inventory.
As a result of the launch issues, Inspire slashed its 2025 earnings guidance by 80% to $0.40 to $0.50 per share, causing its shares to crash $42.04, a decline of approximately 32%, the following day.

Nov 10, 2025, 2:00 PM

Press Release

Inspire Medical Systems Faces Investor Lawsuit Over Inspire V Launch

INSP

Legal Proceedings

Guidance Update

Product Launch

Inspire Medical Systems, Inc. (INSP) is facing a proposed class-action lawsuit alleging the company misled investors about the commercial readiness and demand for its Inspire V sleep apnea device.
The lawsuit claims the Inspire V launch was unsuccessful due to minimal initial demand, attributed to customers' existing inventory of older devices and the company's alleged failure to ensure swift adoption by clinicians and payors.
On August 4, 2025, Inspire disclosed an "elongated timeframe" for the Inspire V launch due to undisclosed headwinds, subsequently slashing its 2025 earnings guidance by 80% to $0.40 to $0.50 per share.
This disclosure led to Inspire's shares crashing $42.04, a decline of approximately 32%, the following day.
The Class Period for the lawsuit is August 6, 2024 – August 4, 2025, with a Lead Plaintiff Deadline of January 5, 2026.

Nov 8, 2025, 9:00 PM

Press Release

Faruqi & Faruqi Investigates Inspire Medical Systems Following Inspire V Launch Setbacks

INSP

Legal Proceedings

Guidance Update

Demand Weakening

Faruqi & Faruqi, LLP is investigating Inspire Medical Systems (INSP) for potential federal securities law violations, alleging the company made false or misleading statements regarding the launch of its Inspire V device.
The investigation follows Inspire Medical's announcement on August 4, 2025, of significant setbacks with the Inspire V launch, including slow rollout due to insufficient training and contracting at treatment centers, billing and reimbursement challenges, weak demand, and excess inventory.
These issues led Inspire Medical to sharply cut its 2025 earnings guidance by more than 80%.
Following these revelations, Inspire's stock price fell more than 32% on August 5, 2025, from $129.95 to $87.91 per share, wiping out approximately $1.2 billion in market capitalization.
Investors who purchased securities between August 6, 2024, and August 4, 2025, have until January 5, 2026, to seek the role of lead plaintiff in the federal securities class action.

Nov 7, 2025, 7:38 PM

Press Release

Filings & Transcripts

View All Documents

Recent SEC filings and earnings call transcripts for INSP.

No recent filings or transcripts found for INSP.